Clinical issues associated with urine testing of substances of abuse

Pharmacotherapy

Volumn 17, Issue 3, 1997, Pages 497-510

  Eskridge, Kimberly D ^a   Guthrie, Sally K ^b,c  

^a BUTLER UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; AMPHETAMINE DERIVATIVE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CANNABINOID; COCAINE; OPIATE DERIVATIVE; PHENCYCLIDINE;

ALCOHOL ABUSE; DRUG DETERMINATION; ENZYME IMMUNOASSAY; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; RADIOIMMUNOASSAY; REVIEW; SUBSTANCE ABUSE; THIN LAYER CHROMATOGRAPHY; URINALYSIS;

CROSS REACTIONS; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; SPECIMEN HANDLING; SUBSTANCE ABUSE DETECTION; SUBSTANCE-RELATED DISORDERS;

EID: 0030950267     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Kleber HD. Our current approach to drug abuse - progress, problems, proposals. N Engl J Med 1994;330:361-5.
2. Caulker-Burnett I. Primary care screening for substance abuse. Nurse Pract 1994;19:42-8.
3. Rupp MT. What the pharmacist should know about urine testing in the workplace. Am Pharm 1988;NS28:19-28.
4. Floren AE. Urine drug screening and the family physician. Am Fam Physician 1994;49:1441-7.
5. Karan LD. Primary care for AIDS and chemical dependence. West J Med 1990;152:538-42.
6. District of Columbia Executive Office of the Mayor, Office of Grants Management and Development. 1992 Crime and Justice Report for the District of Columbia. Washington, DC: Author, 1992:1-49.
7. Saxon AJ, Calsyn DA, Haver VM, Delaney CJ. Clinical evaluation and use of urine screening for drug abuse. West J Med 1988;149:296-303.
8. Sunshine I. Preliminary tests for drugs of abuse. Clin Chem 1988;34:331-3.
9. Substance-Abuse Testing Committee. Critical issues in urinalysis of abused substances: report of the substance-abuse testing committee. Clin Chem 1988;34:605-32.
10. U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. Mandatory guidelines for federal workplace drug testing programs. Fed Register 1994;59:29903-30.
11. Verebey K. Diagnostic laboratory: screening for drug abuse. In. Lowinson JH, Ruiz P, Millman RB, eds. Substance abuse: a comprehensive textbook, 2nd ed. Baltimore: Williams & Wilkins, 1992:425-36.
12. Finkle BS, Black D, Blanke TJ, Butler TJ, Jones GR, Sample RH. Analysis for commonly abused drugs in urine at selected threshold ("cutoff") concentrations [letter]. Clin Chem 1991;37:586-7.
13. Kelly K. The accuracy and reliability of tests for drugs of abuse in urine samples. Pharmacotherapy 1988;8:263-75.
14. Schwartz RH. Urine testing in the detection of drugs of abuse. Arch Intern Med 1988;148:2407-12.
15. Wong SHY. Liquid chromatography and other methodologies for therapeutic drug monitoring and toxicology. In: Wong SHY, ed. Therapeutic drug monitoring and toxicology by liquid chromatography. New York: Marcel Dekker, 1985:39-73.
16. Armbruster DA, Hubster EC, Kaufman MS, Ramon MK. Cloned enzyme donor immunoassay (CEDIA) for drugs-of-abuse screening. Clin Chem 1995;41:92-8.
17. Buechler KF, Moi S, Noar B, et al. Simultaneous detection of seven drugs of abuse by the Triage panel for drugs of abuse. Clin Chem 1992;38:1678-84.
18. Fretthold DW. Drug testing methods and reliability. J Psychoactive Drugs 1990;22:419-28.
19. Lehrer M. Drug screening in the workplace. Clin Lab Med 1987;7:389-400.
20. Wagner JG, Wilkinson PK, Sedman AJ, Kay DR, Weidler DJ. Elimination of alcohol from human blood [letter]. J Pharm Sci 1976;65:152-4.
21. Winger G, Hofmann FG, Woods JH. Depressants of the central nervous system: alcohol, barbiturates, and benzodiazepines. In: Winger G, Hofmann FG, Woods JH, eds. A handbook on drug and alcohol abuse, the biomedical aspects, 3rd ed. New York: Oxford University Press, 1992:56-84.
22. Linnoila M, Stapleton JM, Lister R, Guthrie S, Eckardt M. Effects of alcohol on accident risk. Pathologist 1986;40:36-41.
23. Green KB, Isenschmid DS. Medical review officer interpretation of urine drug test results. Forensic Sci Rev 1995;7:41-59.
24. Schneider LS, Tariot PN, Goldstein B. Therapy with 1-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther 1994;56:750-6.
25. Poklis A, Moore KA. Response of EMIT amphetamine immunoassays to urinary desoxyephedrine following Vicks inhaler use. Ther Drug Monit 1995;17:89-94.
26. Ray O, Ksir C. Stimulants. In: Ray O, Ksir C, eds. Drugs, society and human behavior, 5th ed. St. Louis: Mosby College Publishing, 1990:112-39.
27. Busto U, Bendayan R, Sellers EM. Clinical pharmacokinetics of non-opiate abused drugs. Clin Pharmacokinet 1989;16:1-26.
28. Gunne LM, Anggard E. Pharmacokinetic studies with amphetamines - relation to neuropsychiatric disorders. J Pharmacokinet Biopharm 1973;1:481-95.
29. Sever PS, Caldwell JL, Dring LG, Williams RT. The metabolism of amphetamine in dependent subjects. Eur J Clin Pharmacol 1973;6:177-80.
30. Winger G, Hofmann FG, Woods JH. Central nervous system stimulants: amphetamines, caffeine, and related drugs. In: Winger G, Hofmann FG, Woods JH, eds. A handbook on drug and alcohol abuse, the biomedical aspects, 3rd ed. New York: Oxford University Press, 1992:132-49.
31. Colbert DL, Gallacher G, Mainwaring-Burton RW. Single-reagent polarization fluoroimmunoassay for amphetamine in urine. Clin Chem 1985;31:1193-5.
32. Jain N, Sneath TC, Budd RD, Olson BA. Mass screening and confirmation of seven sympathomimetic amine drugs by EMIT-gas chromatography. J Anal Toxicol 1977;1:233-5.
33. Baselt RC. Urine drug screening by immunoassay: interpretation of results. In: Baselt RC, ed. Advances in analytical toxicology. Foster City, CA: Biomedical Publications, 1984:81-124.
34. Dasgupta A, Saldana S, Kinnaman G, Smith M, Johansen K. Analytical performance evaluation of EMIT. II. Monoclonal amphetamine/methamphetamine assay: more specificity than EMIT-d.a.u. monoclonal amphetamine/methamphetamine assay. Clin Chem 1993;39:104-8.
35. Polkis A, Fitzgerald RL, Hall KV, Saady JJ. EMIT-d.a.u. monoclonal amphetamine/methamphetamine assay. II. Detection of methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine (MDMA). Forensic Sci Int 1993;59:63-70.
36. Polkis A, Hall KV, Eddleton RA, Fitzgerald RL, Saady JJ, Bogema SC. EMIT-d.a.u. monoclonal amphetamine/methamphetamine assay. I. Stereoselectivity and clinical evaluation. Forensic Sci Int 1993;59:49-62.
37. Canfield DV, Lorimer P, Epstein RL. Gas chromatographic analysis of amphetamine derivatives and morpholine-related drugs. J Forensic Sci 1977;22:429-33.
38. Javaid JL, Davis JM. GLC analysis of phenylalkyl primary amines using nitrogen detector. J Pharm Sci 1981;70:813-15.
39. Brettell TA. Analysis of N-mono-trifluoracetyl derivatives of amphetamines analogs by gas chromatography and mass spectrometry. J Chromatogr 1983;257:45-52.
40. Narasimhachari N, Friedel RO. Quantitation of biologically important primary amines as their isothiocyanate derivatives by gas chromatography using nitrogen detection and validation by selected ion monitoring. Clin Chim Acta 1981;110:235-43.
41. Rall TW. Hypnotics and sedatives: ethanol. In: Gilman GG, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's the pharmacologic basis of therapeutics, 8th ed. New York: Pereamon Press, 1990:345-82.
42. Ray O, Ksir C. Depressants. In: Ray O, Ksir C, eds. Drugs, society and human behavior, 5th ed. St. Louis: Mosby College Publishing, 1990:140-54.
43. Barnas C, Rossmann M, Roessler H, Riemer Y, Fleischhacker WW. Benzodiazepines and other psychotropic drugs abused by patients in a methadone maintenance program: familiarity and preference. J Clin Psychopharmacol 1992;12:397-402.
44. Seligmann J, King P. "Roofies": the date-rape drug. Newsweek 1996;Feb 25:54.
45. Greenblatt DJ, Shader RI. Pharmacokinetics of antianxiety agents. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987:1377-86.
46. Ray O, Ksir C. Marijuana and hashish. In: Ray O, Ksir C, eds. Drugs, society and human behavior, 5th ed. St. Louis: Mosby College Publishing, 1990:355-78.
47. Ohlsson A, Lindgren JE, Warden A, Agurell S, Hollister LE, Gillespie HK. Plasma delta-9-tetrahydrocannabinol concentrations and clinical effects after oral and intravenous administration and smoking. Clin Pharmacol Ther 1980;28:409-16.
48. Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther 1983;34:352-63.
49. McBurney LJ, Bobbie BA, Sepp LA. GC/MS and EMIT analyses for delta-9-tetrahydrocannabinol metabolites in plasma and urine of human subjects. J Anal Toxicol 1986;10:56-64.
50. Hunt CA, Jones RT. Tolerance and disposition of tetrahydrocannabinol in man. J Pharmacol Exp Ther 1980;215:35-44.
51. Wall ME, Perez-Reyes M. The metabolism of delta-9-tetrahydrocannabinol and related cannabinoids in man. J Clin Pharmacol 1981;21:178S-89.
52. Perez-Reyes M, DiGuiseppi S, Mason AP, Davis KH. Passive inhalation of marijuana smoke and urinary excretion of cannabinoids. Clin Pharmacol Ther 1983;34:36-41.
53. Cone EJ, Johnson RE. Contact highs and urinary cannabinoid excretion after passive exposure to marijuana smoke. Clin Pharmacol Ther 1986;40:247-56.
54. Cone EJ, Johnson RE, Darwin WD, et al. Passive inhalation of marijuana smoke: urinalysis and room air levels of delta-9-tetrahydrocannabinol. J Anal Toxicol 1987;11:89-96.
55. Mørland J, Bugge A, Skuterud B, Steen A, Wethe GH, Kjeldsen T. Cannabinoids in blood and urine after passive inhalation of cannabis smoke. J Forensic Sci 1985;30:997-1002.
56. Hayden JW. Passive inhalation of marijuana smoke: a critical review. J Subst Abuse 1991;3:85-90.
57. Buchanan JF, McKinney HE, Hayner GN, Inaba DS. Drug abuse. In: Koda-Kimble MA, Young LY, eds. Applied therapeutics: the clinical use of drugs, 5th ed. Vancouver, WA: Applied Therapeutics, 1992:1-29.
58. Inaba T, Stewart DJ, Kalow W. Metabolism of cocaine in man. Clin Pharmacol Ther 1978;23:547-52.
59. Stewart DJ, Inaba T, Lucassen M, Kalow W. Cocaine metabolism: cocaine and norcocaine hydrolysis by liver and serum esterases. Clin Pharmacol Ther 1979;25:464-8.
60. Fletcher SM, Hancock VS. Potential errors on benzoylecgonine and cocaine analysis. J Chromatogr 1981;206:193-5.
61. Cook CE, Jeffcoat AR, Perez-Reyes M. Pharmacokinetic studies of cocaine and phencyclidine in man. In: Barnett G, Chiang CN, eds. Pharmacokinetics and pharmacodynamics of psychoactive drugs. Foster City, CA: Biomedical Publications, 1985:48-74.
62. Ambre J. The urinary excretion of cocaine and metabolites in humans: a kinetic analysis of published data. J Anal Toxicol 1985;9:241-5.
63. Burke WM, Ravi NV, Dhopesh V, Vandegrift B, Maany I. Prolonged presence of metabolite in urine after compulsive cocaine use. J Clin Psychiatry 1990;51:145-8.
64. Allen LV, Stiles ML. Specificity of the EMIT drug abuse urine assay methods. Clin Toxicol 1981;18:1043-65.
65. Kapur BM, Anderson M, Banka T. Testing for drugs of abuse with the Abbott TDx [abstr]. Clin Chem 1987;33:976.
66. Poklis A. Evaluation of TDx cocaine metabolite assay. J Anal Toxicol 1987;11:228-30.
67. Chinn DM, Crouch DJ, Peat MA, Finkle BS, Jennison TA. Gas chromotography - chemical ionization mass spectroscopy of cocaine and its metabolites in biological fluids. J Anal Toxicol 1980;4:37-42.
68. Ray O, Ksir C. Narcotics. In: Ray O, Ksir C, eds. Drugs, society and human behavior, 5th ed. St. Louis: Mosby College Publishing, 1990:298-322.
69. Berkowitz BA, Ngai SH, Yang JC, Hempstead J, Spector S. The disposition of morphine in surgical patients. Clin Pharmacol Ther 1975;17:629-35.
70. Inturrisi CE, Max MB, Foley KM, Schutz M, Shin S-U, Houde RW. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med 1984;310:1213-17.
71. Brunk SF, Delle M. Morphine metabolism in man. Clin Pharmacol Ther 1974;16:51-7.
72. Säwe J, Dahlström B, Paalzow L, Rane A. Morphine kinetics in cancer patients. Clin Pharmacol Ther 1981;30:629-35.
73. Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rail TW, Nies AS, Tayler P, eds. Goodman and Gilman's the pharmacological basis of therapeutics, 8th ed.. New York: Pergamon Press, 1990:485-521.
74. Cleeland R, Christenson J, Usategui-Gomez M, Heveran J, Davis R, Grunberg E. Detection of drugs of abuse by radioimmunoassay: a summary of published data and some new information. Clin Chem 1976;22:712-25.
75. Dubler RE, Heiman D, Raden D. Development of a TDx fluorescence polarization immunoassay (FPIA) for the detection of opiates in urine [abstr]. Clin Chem 1986;32:1052.
76. Poklis A, Graham M, Maginn D, Branch CA, Gantner GE. Phencyclidine and violent deaths in St. Louis, Missouri: a survey of medical examiners' cases from 1977 through 1986. Am J Drug Alcohol Abuse 1990;16:265-74
77. McCarron MM, Schulze BW, Thompson GA, Conder MA, Goetz WA. Acute phencyclidine intoxication: incidence of clinical findings in 1,000 cases. Ann Emerg Med 1981;10:237-42.
78. Zukin SR, Zukin RS. Phencyclidine. In: Lowinson JH, Ruiz P, Millman RB, eds. Substance abuse, a comprehensive textbook, 2nd ed. Baltimore: Williams & Wilkins, 1992:290-302.
79. Winger G, Hofmann FG, Woods JH. Hallucinogens: phencyclidine, LSD, and agents having similar effects. In: Winger G, Hofmann FG, Woods JH, eds. A handbook on drug and alcohol abuse, the biomedical aspects. New York: Oxford University Press, 1992:98-116.
80. Walberg CB, Gupta RC. Quantification of phencyclidine in urine by enzyme immunoassay. J Anal Toxicol 1982;6:97-9.
81. Liu RH. Important considerations in the interpretation of forensic urine drug test results. Forensic Sci Rev 1992;4:51-64.
82. Cody JT. Specimen adulteration in drug urinalysis. Forensic Sci Rev 1990;2:64-75.
83. Mulé SJ, Casella GA. Rendering the "poppy-seed defense" defenseless: identification of 6-monoacetylmorphine in urine by gas chromatography/mass spectroscopy. Clin Chem 1988;34:1427-30.
84. Struempler RE. Excretion of codeine and morphine following ingestion of poppy seeds. J Anal Toxicol 1987;11:97-9.
85. El Sohly MA, Stanford DF, El Sohly HN. Coca tea and urinalysis for cocaine metabolites [letter]. J Anal Toxicol 1986;10:256.
86. Seigel RK, El Sohly MA, Plowman T, Rury PM, Jones RT. Cocaine in herbal tea [letter]. JAMA 1986;255:40.
87. Mikkelsen SL, Ash KO. Adulterants causing false negatives in illicit drug testing. Clin Chem 1988;34:2333-6.
88. Wish ED. Preemployment drug screening. JAMA 1990;264:2676-7.
89. Zwerling C, Ryan J, Orav EJ. The efficacy of preemployment drug screening for marijuana and cocaine in predicting employment outcome. JAMA 1990;264:2639-43.